DGAP-News: European Healthcare Acquisition & Growth Company B.V.
/ Key word(s): AGM/EGM
European Healthcare Acquisition & Growth Company B.V. reconvenes its annual general meeting of shareholders subject to extension of temporary Dutch COVID-19 Act (Tijdelijke wet Justitie en Veiligheid) Munich, 19 May 2022 Today, European Healthcare Acquisition & Growth Company B.V. ("EHC"), a Dutch operators-led special purpose acquisition company listed on Euronext Amsterdam aiming to acquire one or more companies in the European healthcare sector, reconvenes its annual general meeting of shareholders to be held on 30 June 2022 at 10:00 CEST at Gustav Mahlerplein 50, 1082 MA Amsterdam, the Netherlands ("AGM") due to the possibility that the temporary Dutch COVID-19 Act (Tijdelijke wet COVID-19 Justitie en Veiligheid) ("COVID-19 Act") will not be extended. Shareholders will have the opportunity to attend the AGM virtually and in person. The Company urges the shareholders to cast their votes online or by proxy. Shareholders have the option to vote without attending the AGM. In the event that the temporary Dutch COVID-19 Act (Tijdelijke wet COVID-19 Justitie en Veiligheid) will be extended, the annual general meeting 2022 of European Healthcare Acquisition & Growth Company B.V. will be held on 23 June 2022 at 10:00 CEST, by means of a virtual meeting, as included in the notice of the annual general meeting of European Healthcare Acquisition & Growth Company B.V. dated 11 May 2022 (www.ehc-company.com), and the present notice will be retracted. The board of the Company will publish a press release as soon as possible after the Dutch government announces whether or not the COVID-19 Act will continue in force in such a manner that the annual general meeting 2022 of European Healthcare Acquisition & Growth Company B.V. can take place at the originally scheduled date of 23 June 2022. The items on the agenda remain the same and include, amongst others, the adoption of the financial statements for the financial year 2021 and the discharge from liability of the directors. The reconvening notice and the agenda and explanatory notes thereof, and the proxy form are now available on the website of EHC in the 'Investor Relations' section under 'Shareholders Meeting': www.ehc-company.com. The annual report for the financial year 2021, including the financial statements, is available on the website of EHC in the 'Investor Relations' section under 'News & Publications': www.ehc-company.com, where a downloadable version in the European Single Electronic Format (ESEF) is also available. European Healthcare Acquisition & Growth Company B.V. General Enquiries Disclaimer This press release contains information that may qualify as inside information within the meaning of Article 7, paragraph 1, of the EU Market Abuse Regulation. Additional features: File: 2022 AGM (Re)Convocation and Agenda and Explanatory Notes
19.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | European Healthcare Acquisition & Growth Company B.V. |
c/o ALR Treuhand GmbH; Theresienhöhe 28 | |
80339 München | |
Germany | |
ISIN: | NL0015000K10, NL00115000K28 |
WKN: | A3C60V |
Listed: | Amsterdam |
EQS News ID: | 1357281 |
End of News | DGAP News Service |
|
1357281 19.05.2022
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.